Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
92 hedge funds and large institutions have $297M invested in Chinook Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 32 increasing their positions, 27 reducing their positions, and 22 closing their positions.
84% more call options, than puts
Call options by funds: $924K | Put options by funds: $503K
35% more capital invested
Capital invested by funds: $220M → $297M (+$77M)
19% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 27
10% less funds holding
Funds holding: 102 → 92 (-10)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$67.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.71M |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$4.13M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.56M |
| 5 |
AG
Artal Group
Luxembourg
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.25M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.12M |
| 3 |
QF
QVT Financial
New York
|
-$2.17M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$1.9M |
| 5 |
Millennium Management
New York
|
-$1.74M |
KDNY Hedge Fund Activity: Q3 2016 in Review
92 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2016, worth a combined $297M — up 35% from $220M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of KDNY and 13 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 32 added.
The largest buyer was Wellington Management Group, adding an estimated $67.2M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $3.25M sold.
- 92 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2016, down from 102 in Q2 2016.
- Funds reported $297M of Chinook Therapeutics, Inc. Common Stock stock for Q3 2016, up 35% quarter-over-quarter.
- 13 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2016 and 22 closed out, a net change of -9 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q3 2016 was Wellington Management Group, an estimated $67.2M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2016 was Oxford Asset Management, an estimated $3.25M sold.
Based on aggregated 13F filings for Q3 2016.